Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies
NCT04459273Phase 1Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga FAPI-46 in cancer, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues. Started Aug 2020; status: active, not recruiting.
02
Drugs
68Ga FAPI-46
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04459273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04459273.